PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Hynek Pikhart | Fernando Pires Hartwig | Joshua C Denny | Uwe Völker | Dan M Roden | Beverley Balkau | H Lester Kirchner | Philippe Froguel | Yanchun Bao | Meena Kumari | Melissa Smart | Alexander Teumer | Max Moldovan | Simonetta Guarrera | Giuseppe Matullo | Yoav Ben-Shlomo | Archie Campbell | Henry Völzke | Andrew Nicolaides | Mariza de Andrade | Michael V Holmes | Lars Lind | Anubha Mahajan | Marylyn D Ritchie | Marcus Dörr | Martin O'Donnell | Nicholas J Wareham | Torben Hansen | Martin Bobak | Abdonas Tamosiunas | John Attia | Niels Grarup | Allan Linneberg | Claudia Langenberg | Erik Ingelsson | Stefan Gustafsson | Diederick E Grobbee | Michiel L Bots | Amélie Bonnefond | Harold Snieder | Elina Hyppönen | Salim Yusuf | Albert Hofman | Lars Bertram | Robin Young | Terrie Kitchner | Hakon Hakonarson | Sandosh Padmanabhan | Ruzena Kubinova | John Wright | Mika Kivimaki | Abbas Dehghan | Catherine A McCarty | Oluf Pedersen | Adelaida Sanchez-Galvez | Stela McLachlan | Johann Willeit | Robert Scott | Terrie E. Kitchner | Alex P Reiner | Elisabeth Steinhagen-Thiessen | David S Carrell | Guillaume Pare | Pedro Marques-Vidal | Jill P Pell | Anke H Maitland-van der Zee | Daniel I Chasman | Paul M Ridker | Pim van der Harst | Eric B Larson | Folkert W Asselbergs | Ilja Demuth | Jian'an Luan | Naveed Sattar | Kristina Norman | Stefan Coassin | Giovanni Fiorito | Markus M Lerch | J. Pell | O. Franco | A. Hofman | A. Uitterlinden | C. Carty | A. Reiner | H. Hakonarson | T. Hansen | O. Pedersen | N. Grarup | S. Yusuf | P. Ridker | D. Chasman | H. Völzke | John Wright | S. Humphries | A. Hingorani | B. Horta | A. Dehghan | C. McCarty | D. Roden | D. Grobbee | P. Whincup | N. Sattar | H. Snieder | E. Ingelsson | P. Harst | B. Balkau | P. Froguel | S. Coassin | L. Lind | M. O’Donnell | J. Denny | M. Brilliant | N. Wareham | A. Mahajan | S. Gustafsson | E. Hyppönen | C. Power | P. Marques‐Vidal | S. Kiechl | J. Willeit | M. Ritchie | A. Nicolaides | M. Bots | G. Matullo | A. Teumer | U. Völker | T. Kitchner | Tian Liu | L. Bertram | S. Baumeister | J. Attia | M. de Andrade | E. Holliday | Danny J. Smith | E. Larson | F. Hartwig | A. Campbell | J. Luan | S. Padmanabhan | M. A. Said | R. Scott | R. N. Eppinga | C. Langenberg | P. van der Harst | D. Mook-Kanamori | T. Meade | A. Bonnefond | Y. Ben-Shlomo | H. Kirchner | J. Price | M. Kumari | M. Kivimaki | E. Steinhagen-Thiessen | I. Demuth | L. Bertram | Riyaz S. Patel | G. Paré | M. Bobák | J. Casas | R. Kubínová | A. Linneberg | S. Malyutina | S. McLachlan | A. Pająk | H. Pikhart | A. Tamosiunas | Y. Schouw | M. Lerch | M. Dörr | D. Carrell | N. Verweij | I. Ford | F. Asselbergs | L. Lange | R. Young | D. Lyall | J. Ward | M. Holmes | R. Morris | L. Husemoen | G. Fiorito | S. Guarrera | M. Andrade | Y. T. van der Schouw | N. Onland-Moret | C. Sacerdote | D. Thuillier | R. Pazoki | J. Cooper | Y. Bao | M. Smart | B. Keating | D. Crosslin | A. Panayiotou | K. Willeit | A. H. Maitland‐van der Zee | D. Mason | B. Cariou | K. Norman | E. V. Iperen | M. Chong | Stephen J Hancock | D. Preiss | D. Swerdlow | M. Moldovan | Z. Fairhurst-Hunter | A. Schmidt | Tian Liu | Riyaz S Patel | David R Crosslin | Niek Verweij | Murray Brilliant | Cara Carty | Ian Ford | Yvonne T van der Schouw | Carlotta Sacerdote | Aroon D Hingorani | Richard Morris | Peter Whincup | Stefan Kiechl | Steve E Humphries | Bertrand Cariou | Dan Mason | E. V. van Iperen | G. Hovingh | Andrie G Panayiotou | Juan-Pablo Casas | Bernardo Lessa Horta | Brendan J Keating | G Kees Hovingh | Karin Willeit | Tom Meade | Leslie A Lange | David Preiss | Dennis O Mook-Kanamori | Joey Ward | Daniel J Smith | Jackie F Price | A. M. Zee | C. Welch | Michael Chong | N Charlotte Onland-Moret | Amand F Schmidt | Daniel I Swerdlow | Andre Uitterlinden | Raha Pazoki | Zammy Fairhurst-Hunter | Donald M Lyall | Christine Power | Erik van Iperen | Juri Demuth | Goya Wanamethee | Catherine Welch | Sofia Malyutina | Andrzej Pająk | Lise Lotte Nystrup Husemoen | Kenneth Starup Simonsen | Jackie Cooper | Stephen Hancock | Elizabeth Holliday | M Abdullah Said | Ruben N Eppinga | Tim Christen | Oscar Franco | Sebastian Baumeister | Ekaterina V Baranova | Dorothée Thuillier | Juri Demuth | Goya Wanamethee | A. Sánchez-Gálvez | T. Christen | E. Baranova | K. Simonsen | R. Patel | P. Marques-Vidal | P. van der harst | M. V. Holmes | A. Tamošiūnas | Mika Kivimäki | Riyaz S. Patel | Max Moldovan | Mariza de Andrade | A. Uitterlinden | Dorothée Thuillier | A. Hofman | R. Scott | M. Kivimäki | R. Scott | T. Hansen | J. Cooper | J. Price | A. Campbell | G. Hovingh

[1]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[2]  Tom R. Gaunt,et al.  Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study , 2017 .

[3]  Sara M. Willems,et al.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[4]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[5]  Stephen C. J. Parker,et al.  The genetic architecture of type 2 diabetes , 2016, Nature.

[6]  Jennifer G. Robinson,et al.  No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies , 2016, European heart journal.

[7]  Malte Kelm,et al.  Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. , 2015, Annals of internal medicine.

[8]  R. Mägi,et al.  Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes , 2015, Diabetes.

[9]  J. Kastelein,et al.  Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. , 2015, JAMA.

[10]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[11]  Ross M. Fraser,et al.  Genetic studies of body mass index yield new insights for obesity biology , 2015, Nature.

[12]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[13]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[14]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[15]  Ross M. Fraser,et al.  Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits , 2013, PLoS genetics.

[16]  Tom R. Gaunt,et al.  Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. , 2013, European heart journal.

[17]  Shah Ebrahim,et al.  Statins for the primary prevention of cardiovascular disease (Review) , 2011 .

[18]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[19]  Tom R. Gaunt,et al.  Secretory Phospholipase A2-IIA and Cardiovascular Disease , 2013, Journal of the American College of Cardiology.

[20]  A. Butterworth,et al.  Use of Mendelian randomisation to assess potential benefit of clinical intervention , 2012, BMJ : British Medical Journal.

[21]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[22]  Tanya M. Teslovich,et al.  Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways , 2012, Nature Genetics.

[23]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[24]  A. Syvänen,et al.  Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[26]  G. Yancopoulos,et al.  Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. , 2012, The New England journal of medicine.

[27]  A Rogier T Donders,et al.  Dealing with missing outcome data in randomized trials and observational studies. , 2012, American journal of epidemiology.

[28]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[29]  Christian Gieger,et al.  Edinburgh Research Explorer Common variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and nonglycemic pathways , 2010 .

[30]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[31]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[32]  Annik Prat,et al.  PCSK9‐deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities , 2010, FEBS letters.

[33]  Christian Gieger,et al.  New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk , 2010, Nature Genetics.

[34]  Meena Kumari,et al.  Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms , 2010, Circulation.

[35]  Michel Krempf,et al.  PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. , 2009, Biochemical and biophysical research communications.

[36]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[37]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[38]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[39]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[40]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[41]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[42]  M. Kendall.  Statistical Methods for Research Workers , 1937, Nature.

[43]  R. Fisher,et al.  Statistical Methods for Research Workers , 1930, Nature.